Quality of end‐of‐life care in patients with hematologic malignancies: A retrospective cohort study. Issue 10 (18th February 2014)

• Record Type: Journal Article
• Authors: Hui, David; Didwaniya, Neha; Vidal, Marieberta; Shin, Seong Hoon; Chisholm, Gary; Roquemore, Joyce; Bruera, Eduardo
• Is Part Of: Cancer. Volume 120:Issue 10(2014)
• Page Start: 1572
• Page End: 1578
• Publication Date: 2014-02-18
• Subjects: Cancer -- Periodicals; Cancer -- Cytopathology -- Periodicals; 616.99405
• DOI: 10.1002/cncr.28614
• Languages: English
• ISSNs: 0008-543X

Abstract

<abstract abstract-type="main"> <title> <x xml:space="preserve">Abstract</x> </title> <sec id="cncr28614-sec-0001" sec-type="section"> <title>BACKGROUND</title> <p>To the authors' knowledge, only limited data are available regarding the quality of end‐of‐life care for patients with hematologic malignancies. In this retrospective cohort study, the quality of end‐of‐life care was compared between patients with hematologic malignancies and those with solid tumors.</p> </sec> <sec id="cncr28614-sec-0002" sec-type="section"> <title>METHODS</title> <p>All adult patients who died of advanced cancer between September 1, 2009 and February 28, 2010 while under the care of the study institution were included. The authors collected baseline demographics and end‐of‐life care indicators, including emergency room visits, hospitalization, intensive care unit admissions, and systemic cancer therapy use within the last 30 days of life.</p> </sec> <sec id="cncr28614-sec-0003" sec-type="section"> <title>RESULTS</title> <p>Of a total of 816 decedents, 113 (14%) had hematologic malignancies. In the last 30 days of life, patients with hematologic malignancies were more likely to have emergency room visits (54% vs 43%; <italic>P</italic> = .03), hospital admissions (81% vs 47%; <italic>P</italic> < .001), ≥ 2 hospital admissions (23% vs 10%; <italic>P</italic> < .001), > 14 days of hospitalization (38% vs 8%; <italic>P</italic> < .001), intensive care unit admissions (39% vs 8%; <italic>P</italic> < .001) and death (33% vs 4%; <italic>P</italic> < .001), chemotherapy use (43% vs 14%; <italic>P</italic> < .001), and targeted therapy use (34% vs 11%; <italic>P</italic> < .001) compared with patients with solid tumors. Patients with hematologic malignancies were also less likely to have palliative care unit admissions (8% vs 17%; <italic>P</italic> = .02). The composite score for aggressiveness of care (with 0 indicating the best and 6 indicating the worst) was significantly higher among patients with hematologic malignancies compared with those with solid tumors (median, 2 vs 0; <italic>P</italic> < .001). On multivariate analysis, hematologic malignancy was found to be a significant factor associated with aggressive end‐of‐life care (odds ratio, 6.6; 95% confidence interval, 4.1‐10.7 [<italic>P</italic> < .001]).</p> </sec> <sec id="cncr28614-sec-0004" sec-type="section"> <title>CONCLUSIONS</title> <p>The results of the current study indicate that patients with hematologic malignancies received more aggressive care at the end of life. <bold><italic>Cancer</italic> 2014;120:1572–1578.</bold> © <italic>2014 American Cancer Society</italic>.</p> </sec> </abstract>